Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Tissue Repair

Glow

GLOW blend; GHK-Cu + BPC-157 + TB-500; skin + tissue repair blend

Three-component regenerative blend (matrikine + cytoprotective + actin-regulator)

This Glow entry draws on 4 cited sources published 2005 to 2018. The evidence available is graded Anecdotal on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
Three-component regenerative blend (matrikine + cytoprotective + actin-regulator)
Drug class
Tissue Repair
Structure
Vendor canonical 70 mg vial (Peptide Sciences): GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg in fixed ratios. Compounded variants vary
Route
SC injection
Half-life
Composite: hours (BPC-157 / GHK-Cu) to days (TB-500 tissue uptake)
Evidence tier
Anecdotal
Availability
Compounding Restricted

Mechanism of action

Layered remodelling: GHK-Cu's copper-peptide matrikine signal upregulates collagen and elastin transcription and engages roughly 4,000 wound-healing genes; BPC-157 drives angiogenesis via VEGFR2 and stabilises epithelial / connective-tissue repair; TB-500 sequesters G-actin to enable cell migration and amplifies stem-cell mobilisation. Together: matrix synthesis + vessel-bed repair + cell-migration substrate.

Reported areas of research

Skin regeneration; injury and wound recovery; collagen and elastin synthesis support; dermal remodelling; commonly the entry-point recovery blend before stepping up to Klow (which adds an anti-inflammatory arm)

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

Typical SC protocols deliver ~250-500 mcg per component daily for 4-6 week loading cycles. Confirm per-component dose from the vial total before reconstitution

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

No human trials of the combined formulation; TB-500 WADA-banned with theoretical pro-proliferative concerns; chronic GHK-Cu raises copper-accumulation considerations at high doses; injection-site reactions

Compared with

Glow has published head-to-head comparisons with 9 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.

Frequently asked questions

What dosing is reported for Glow in research literature?

Published peptide research reports the following dosing approach for Glow: Typical SC protocols deliver ~250-500 mcg per component daily for 4-6 week loading cycles. Confirm per-component dose from the vial total before reconstitution. This is a research reference, not a clinical recommendation.

How is Glow administered in research?

Glow is administered via the following routes in published studies: SC injection.

What is the reported half-life of Glow?

The reported half-life of Glow is Composite: hours (BPC-157 / GHK-Cu) to days (TB-500 tissue uptake).

Is Glow FDA-approved?

No. Glow is not an FDA-approved drug. PeptideHelper.org catalog status: Compounding Restricted.

What level of evidence supports Glow?

The current evidence base for Glow is best characterised as: Anecdotal. See the methodology page for the full evidence-tier rubric.

What side effects are reported for Glow?

Known concerns reported in the literature for Glow include: No human trials of the combined formulation; TB-500 WADA-banned with theoretical pro-proliferative concerns; chronic GHK-Cu raises copper-accumulation considerations at high doses; injection-site reactions. Always consult a qualified clinician before any human use.

Is there anyone who should not use Glow?

No formal contraindications are established for Glow, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: No human trials of the combined formulation; TB-500 WADA-banned with theoretical pro-proliferative concerns; chronic GHK-Cu raises copper-accumulation considerations at high doses; injection-site reactions. Always consult a qualified clinician before any human use.

How does Glow work?

The mechanism of action reported for Glow in the literature: Layered remodelling: GHK-Cu's copper-peptide matrikine signal upregulates collagen and elastin transcription and engages roughly 4,000 wound-healing genes; BPC-157 drives angiogenesis via VEGFR2 and stabilises epithelial / connective-tissue repair; TB-500 sequesters G-actin to enable cell migration and amplifies stem-cell mobilisation. Together: matrix synthesis + vessel-bed repair + cell-migration substrate..

What is Glow studied for?

Glow has been studied in the published literature for: Skin regeneration; injury and wound recovery; collagen and elastin synthesis support; dermal remodelling; commonly the entry-point recovery blend before stepping up to Klow (which adds an anti-inflammatory arm). These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is Glow?

Glow is classified as: Three-component regenerative blend (matrikine + cytoprotective + actin-regulator). Also known as: GLOW blend; GHK-Cu + BPC-157 + TB-500; skin + tissue repair blend.

Drug class

Research focus area

All peptides studied for Tissue Repair, ranked by evidence tier and regulatory status.

Primary sources

  1. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015. PMID 26236731
  2. Sikiric P et al. Stable gastric pentadecapeptide BPC 157 — review of pharmacology. Curr Pharm Des 2018. PMID 29804522
  3. Goldstein AL et al. Thymosin beta4 — actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005. PMID 16099219
  4. Note: Glow is a vendor-marketed three-peptide blend with no published human trials of the combination; cited papers describe each component separately.

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…